A Phase I, Open-Label, Two-stage, Randomized, Crossover, Comparative Pharmacokinetic and Safety Study of Two Formulations of CO-1.01 for Injection in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I, Open-Label, Two-stage, Randomized, Crossover, Comparative Pharmacokinetic and Safety Study of Two Formulations of CO-1.01 for Injection in Patients With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Gemcitabine elaidate (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Jun 2013 Results published in the Journal of Clinical Pharmacology.
    • 13 Jun 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has not been met.
    • 15 Feb 2013 Status changed from suspended to discontinued, based on a Clavis Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top